PL2993186T3 - Przeciwciało monoklonalne i sposób jego otrzymywania - Google Patents

Przeciwciało monoklonalne i sposób jego otrzymywania

Info

Publication number
PL2993186T3
PL2993186T3 PL15171431T PL15171431T PL2993186T3 PL 2993186 T3 PL2993186 T3 PL 2993186T3 PL 15171431 T PL15171431 T PL 15171431T PL 15171431 T PL15171431 T PL 15171431T PL 2993186 T3 PL2993186 T3 PL 2993186T3
Authority
PL
Poland
Prior art keywords
monoclonal antibody
monoclonal
antibody
Prior art date
Application number
PL15171431T
Other languages
English (en)
Inventor
Ramakrishnan Melarkode
Pradip Nair
Sundaraj David Rajkumar
Kedarnath Nanjund Sastry
Monalisa Chatterji
Laxmi Adhikary
Hema Balasubramanian
Jose Enrique Montero Casimiro
Josefa Lombardero Valladares
Rolando Perez Rodriguez
Original Assignee
Biocon Limited
Centro De Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41064805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2993186(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocon Limited, Centro De Inmunologia Molecular filed Critical Biocon Limited
Publication of PL2993186T3 publication Critical patent/PL2993186T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL15171431T 2008-03-14 2008-09-04 Przeciwciało monoklonalne i sposób jego otrzymywania PL2993186T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN650CH2008 2008-03-14
PCT/IN2008/000562 WO2009113083A1 (en) 2008-03-14 2008-09-04 A monoclonal antibody and a method thereof
EP15171431.8A EP2993186B1 (en) 2008-03-14 2008-09-04 A monoclonal antibody and a method thereof
EP08873217A EP2265644A4 (en) 2008-03-14 2008-09-04 MONOCLONAL ANTIBODY AND CORRESPONDING METHOD

Publications (1)

Publication Number Publication Date
PL2993186T3 true PL2993186T3 (pl) 2020-02-28

Family

ID=41064805

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15171431T PL2993186T3 (pl) 2008-03-14 2008-09-04 Przeciwciało monoklonalne i sposób jego otrzymywania

Country Status (26)

Country Link
US (7) US8524233B2 (pl)
EP (2) EP2993186B1 (pl)
JP (3) JP2011513479A (pl)
KR (1) KR20100126811A (pl)
CN (1) CN101970493A (pl)
AR (1) AR072247A1 (pl)
AU (1) AU2008352540B2 (pl)
BR (1) BRPI0822447A2 (pl)
CA (1) CA2716919C (pl)
CL (1) CL2009000618A1 (pl)
CO (1) CO6331445A2 (pl)
DK (1) DK2993186T3 (pl)
EA (1) EA201001467A1 (pl)
ES (1) ES2759075T3 (pl)
HK (1) HK1223941A1 (pl)
IL (1) IL207917A0 (pl)
MX (1) MX2010010085A (pl)
MY (1) MY159517A (pl)
NZ (1) NZ587632A (pl)
PL (1) PL2993186T3 (pl)
PT (1) PT2993186T (pl)
TW (1) TWI485160B (pl)
UA (1) UA104587C2 (pl)
UY (1) UY31710A (pl)
WO (1) WO2009113083A1 (pl)
ZA (1) ZA201005843B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101482959B1 (ko) * 2006-12-26 2015-01-15 센트로 데 인뮤놀러지아 모레큘러 Ｂ-세포 만성 림프구성 백혈병의 진단 및 치료에 유용한 종양 세포에서 세포사멸을 유도할 수 있는 약학 조성물
WO2009113083A1 (en) 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
SG11201600067YA (en) * 2013-07-23 2016-02-26 Biocon Ltd Methods for controlling fucosylation levels in proteins
EP3024485B1 (en) * 2013-07-23 2020-11-18 Biocon Limited Use of a cd6 binding partner and method based thereon
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN104497141B (zh) * 2014-12-31 2017-10-10 百泰生物药业有限公司 抗人cd6分子的治疗性抗体
JP6930916B2 (ja) * 2015-02-12 2021-09-01 ユニヴァーシティ オブ サザン カリフォルニアＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｓｏｕｔｈｅｒｎ Ｃａｌｉｆｏｒｎｉａ 疾患予防および治療における成長ホルモン受容体の遮断剤
US10562975B2 (en) 2016-06-15 2020-02-18 The Regents Of The University Of Michigan CD6 antibody for treatment of T-cell mediated diseases or disorders
JP7065085B2 (ja) * 2016-10-18 2022-05-11 バイオコン・リミテッド Ｃｄ６のリン酸化を低減させるためのイトリズマブの使用
ES2991182T3 (es) * 2016-10-21 2024-12-02 Biocon Ltd Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus
CN108178797B (zh) * 2017-12-29 2020-12-01 西南大学 一种抗家蚕BmSRC多克隆抗血清、制备方法及应用
CN112424226B (zh) 2018-02-27 2025-03-14 平衡生物科技股份有限公司 用于治疗重度哮喘的抗cd6抗体
US12281151B2 (en) 2018-06-29 2025-04-22 City Of Hope CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders
BR112021016967A2 (pt) * 2019-02-26 2021-11-23 Equillium Inc Composições de anticorpo anti-cd6 e métodos para tratar lúpus
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
CA3231281A1 (en) 2021-09-08 2023-03-16 Yanelda De Los Angeles Garcia Vega Use of anti-cd6 monoclonal antibodies in the prevention of cellular and organ damage resulting from hyper-inflammatory response

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US699755A (en) 1902-03-06 1902-05-13 Ira G Hoag Train-order box in connection with semaphores.
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP0631783A1 (en) 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
US5998172A (en) 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
WO1995012614A1 (en) 1993-11-02 1995-05-11 Duke University Cd6 ligand
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CU22584A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
KR20000064710A (ko) 1996-03-20 2000-11-06 제넨테크, 인코포레이티드 인테그린, 특히 ανβ3 인테그린에 대하여 특이 활성을갖는 3환식 화합물, 그 제조방법 및 그 제조를 위한 중간체, 의약으로서의 그 용도 및 그를 포함한 약제 조성물
WO1998043089A1 (en) 1997-03-03 1998-10-01 Bristol-Myers Squibb Company Monoclonal antibodies to human cd6
WO1998047531A2 (en) * 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
WO2000058362A1 (en) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
WO2000067796A1 (en) 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
WO2001070984A2 (en) * 2000-03-16 2001-09-27 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
HK1054316A1 (zh) * 2000-05-26 2003-11-28 Smithkline Beecham Corporation 用於治疗rank配体介导疾病的抗-rank配体单克隆抗体
ES2192128B1 (es) 2001-04-27 2005-01-01 Universidad De Vigo Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.
MXPA04000747A (es) 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
US20040091490A1 (en) 2002-08-28 2004-05-13 Robert Johnson Stable pH optimized formulation of a modified antibody
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
MXPA05010555A (es) 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
AU2005214382B2 (en) * 2004-02-19 2011-08-04 Genentech, Inc. CDR-repaired antibodies
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
PA8661401A1 (es) 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
WO2007142667A2 (en) 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
CA2654794A1 (en) 2006-06-14 2007-12-21 Imclone Systems Incorporated Lyophilized formulations of anti-egfr antibodies
CL2007003583A1 (es) 2006-12-11 2008-07-18 Hoffmann La Roche Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
CN101199483B (zh) 2006-12-14 2011-01-26 上海中信国健药业股份有限公司 一种稳定的抗her2人源化抗体制剂
KR101482956B1 (ko) * 2006-12-26 2015-01-15 센트로 데 인뮤놀러지아 모레큘러 류마티스 관절염의 진단 및 치료에 사용되는 항-ｃｄ6 단일클론성 항체를 포함하는 약학 조성물
KR101482959B1 (ko) 2006-12-26 2015-01-15 센트로 데 인뮤놀러지아 모레큘러 Ｂ-세포 만성 림프구성 백혈병의 진단 및 치료에 유용한 종양 세포에서 세포사멸을 유도할 수 있는 약학 조성물
CA2674608A1 (en) 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
NZ579251A (en) 2007-02-28 2012-06-29 Schering Corp Engineered anti-il-23r antibodies
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
EP2170268A2 (en) 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
WO2009037190A2 (en) 2007-09-21 2009-03-26 F. Hoffmann-La Roche Ag Pharmaceutical formulation for il-ir antibody
WO2009113083A1 (en) 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
EP2501408B1 (en) 2009-11-20 2020-05-27 Biocon Limited Formulations of antibody
CN102559636B (zh) 2011-12-30 2014-03-12 百泰生物药业有限公司 用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法
SG11201600067YA (en) 2013-07-23 2016-02-26 Biocon Ltd Methods for controlling fucosylation levels in proteins
EP3024485B1 (en) 2013-07-23 2020-11-18 Biocon Limited Use of a cd6 binding partner and method based thereon
US10562975B2 (en) 2016-06-15 2020-02-18 The Regents Of The University Of Michigan CD6 antibody for treatment of T-cell mediated diseases or disorders
WO2018024896A1 (en) 2016-08-05 2018-02-08 INSERM (Institut National de la Santé et de la Recherche Médicale) EX VIVO GENERATION OF γδ FOXP3+ REGULATORY T CELLS AND THERAPEUTIC USES THEREOF
JP7065085B2 (ja) 2016-10-18 2022-05-11 バイオコン・リミテッド Ｃｄ６のリン酸化を低減させるためのイトリズマブの使用
ES2991182T3 (es) 2016-10-21 2024-12-02 Biocon Ltd Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus
CN112424226B (zh) 2018-02-27 2025-03-14 平衡生物科技股份有限公司 用于治疗重度哮喘的抗cd6抗体
BR112021016967A2 (pt) 2019-02-26 2021-11-23 Equillium Inc Composições de anticorpo anti-cd6 e métodos para tratar lúpus
US20230151107A1 (en) 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
JP2023552762A (ja) 2020-12-04 2023-12-19 エクイリウム，インコーポレイテッド Ｃｄ６ｈｉｇｈ細胞を選択的に標的化してｔｅｆｆ細胞の活性を低下する方法

Also Published As

Publication number Publication date
TWI485160B (zh) 2015-05-21
US20110002939A1 (en) 2011-01-06
AU2008352540B2 (en) 2012-06-28
US11981743B2 (en) 2024-05-14
CN101970493A (zh) 2011-02-09
JP5856209B2 (ja) 2016-02-09
ES2759075T3 (es) 2020-05-07
EA201001467A1 (ru) 2011-06-30
US9670285B2 (en) 2017-06-06
US20140031529A1 (en) 2014-01-30
US10000573B2 (en) 2018-06-19
US20240417483A1 (en) 2024-12-19
US20210122829A1 (en) 2021-04-29
TW201000125A (en) 2010-01-01
CA2716919C (en) 2015-01-20
US20170281808A1 (en) 2017-10-05
EP2265644A4 (en) 2011-04-27
AU2008352540A1 (en) 2009-09-17
EP2993186A1 (en) 2016-03-09
EP2993186B1 (en) 2019-09-04
US8524233B2 (en) 2013-09-03
WO2009113083A1 (en) 2009-09-17
MY159517A (en) 2017-01-13
US9217037B2 (en) 2015-12-22
HK1223941A1 (en) 2017-08-11
EP2265644A1 (en) 2010-12-29
DK2993186T3 (da) 2019-11-25
JP2011513479A (ja) 2011-04-28
UA104587C2 (ru) 2014-02-25
CO6331445A2 (es) 2011-10-20
US20180258179A1 (en) 2018-09-13
AR072247A1 (es) 2010-08-18
JP2014159425A (ja) 2014-09-04
PT2993186T (pt) 2019-11-29
KR20100126811A (ko) 2010-12-02
BRPI0822447A2 (pt) 2015-06-16
MX2010010085A (es) 2011-03-29
US20160168256A1 (en) 2016-06-16
CA2716919A1 (en) 2009-09-17
US10669346B2 (en) 2020-06-02
UY31710A (es) 2009-11-10
ZA201005843B (en) 2011-04-28
CL2009000618A1 (es) 2011-05-27
NZ587632A (en) 2012-06-29
JP2014065711A (ja) 2014-04-17
IL207917A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
ZA201005843B (en) A monoclonal antibody and a method thereof
SG10201601279SA (en) Monoclonal Antibody STRO-4
EP2331579A4 (en) MONOCLONAL ANTIBODIES
IL201082A0 (en) Bispecific antibodies and methods for production thereof
EP2021373A4 (en) MONOCLONAL ANTIBODY VCAM-1 SPECIFIC
EP2374883A4 (en) ANTI-CD4 ANTIBODIES
EP2121756A4 (en) ANTIBODIES AND PROCESS FOR THEIR PREPARATION AND USE
ZA200809662B (en) Modified humanised anti-interleukin-18 antibodies
SI2510011T1 (sl) Monoklonska protitelesa, ki veĹľejo B7H6 in njihova uporaba
ZA201005348B (en) Humanized anti-c5ar antibodies
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
ZA201207484B (en) Humanized anti-egfl7 antibodies and methods using same
IL204835A0 (en) Humanized antibody
IL192419A0 (en) Anti-ephb4 antibodies and methods using same
IL218621A0 (en) Monoclonal antibodies
IL231891A (en) Anti-ephrinb2 antibodies and methods for their use
SI2094728T1 (sl) Postopki za uporabo za humano-adaptivnost monoklonskih protiteles
ZA201103941B (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
IL206898A0 (en) HUMANIZED ANTI-HUMAN a9-INTEGRIN ANTIBODY AND USES THEREOF
HK1152531A (en) A monoclonal antibody and a method thereof
ZA200806053B (en) Anti-EphB4 antibodies and methods using same
GB0804686D0 (en) Humanized antibody
GB0804687D0 (en) Humanized antibody
GB0804684D0 (en) Humanized antibody
GB0706965D0 (en) Humanized antibody